As part of this joint development agreement, Bayer looks to leverage Azitra's microbiome modulation technology with a focus on Staphylococcus epidermidis bacterial strains, targeting a number of skin conditions, including eczema and atopic dermatitis. Azitra recently raised a $14 million Series A led by KdT Ventures and Bios Partners, bringing its total funding to $20.8 million. A partnership with a big industry player like Bayer is likely to help validate Azitra's technology potential and pave way for future licensing agreements. As the skin microbiome space gains momentum, industry partnerships will be key to accelerating the commercialization timelines of skin microbiome-modulating products.
For the original news article,